Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo

13 Oct 2020

Abstract excerpt

// Tiziano Ongaro 1 , 2 , Baptiste Gouyou 1 , Marco Stringhini 3 , Riccardo Corbellari 1 , 4 , Dario Neri 3 and Alessandra Villa 1 1 Philochem AG, Otelfingen, Switzerland 2 University School for Advanced Studies IUSS Pavia, Pavia, Italy 3 Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, ETH Zürich, Zürich, Switzerland 4 University of Trento, CiBIO, Department of Cellular,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33110477
DOI: 10.18632/oncotarget.27726

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivoPMID 33110477Read ↗

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 <sup>+</sup> T cell activity and synergizes with immune check-point inhibitorsSemantic proximity Read ↗

Enhancing CAR T cell therapy using Fab-Based Constitutively Heterodimeric Cytokine ReceptorsSemantic proximity Read ↗

Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imagingSemantic proximity Read ↗

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.Semantic proximity Read ↗

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protectionSemantic proximity Read ↗

Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.Semantic proximity Read ↗

Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and ChallengesSemantic proximity Read ↗

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read ↗

Next-generation flexible formats of VNAR domains expand the drug platform's utility and developabilitySemantic proximity Read ↗

MiniCARbids: Minimalistic human binding domains specifically tailored to CAR T applicationsSemantic proximity Read ↗

Antibody discovery ex vivo accelerated by the LacO/LacI regulatory network.Semantic proximity Read ↗

Dual Immune Checkpoint and Cytokine Receptor Modulation by an Engineered Human CTLA-4/IL-10 Bispecific Fusion ProteinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.